MUC1 and neoplasm: To explore the optimal immunization cycles of the recombinant MUC1-MBP vaccine including the recombinant MUC1-MBP protein and CpG 2006, mice received different numbers of immunizations, as shown in Figure 1A. One week after the final immunization, the mice were subjected to tumor challenge by subcutaneous injection of human MUC1-overexpressing mouse B16 melanoma cells (B16-MUC1).